Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;31(4):691-9.
doi: 10.1377/hlthaff.2012.0174.

Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates


Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates

Seth A Seabury et al. Health Aff (Millwood). .


There is a growing emphasis on promoting medical treatments that provide the most benefits relative to their costs. However, objective criteria for determining the value patients receive from treatment are lacking. This study used data on the treatment choices of terminally ill patients to estimate the value they associate with care. We found that patients place high valuations on metastatic cancer therapy--on average, twenty-three times higher than its cost--and that other traditional methods used to estimate the value of these treatments for patients significantly undervalues how patients view them. Our methods provide another framework for an evidence-based approach to assessing the value of treatments for terminal illness.

Comment in

  • Willingness to pay for cancer therapy.
    Silver J, Lopert R. Silver J, et al. Health Aff (Millwood). 2012 Aug;31(8):1909; author reply 1909. doi: 10.1377/hlthaff.2012.0712. Health Aff (Millwood). 2012. PMID: 22869668 No abstract available.

Similar articles

  • Cost of illness in patients with metastatic colorectal cancer.
    Song X, Zhao Z, Barber B, Gregory C, Cao Z, Gao S. Song X, et al. J Med Econ. 2011;14(1):1-9. doi: 10.3111/13696998.2010.536870. Epub 2010 Nov 25. J Med Econ. 2011. PMID: 21108534
  • Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
    Sorensen SV, Goh JW, Pan F, Chen C, Yardley D, Martín M, Knopf K, Benedict A, Giorgetti C, Iyer S. Sorensen SV, et al. Int J Technol Assess Health Care. 2012 Jan;28(1):12-21. doi: 10.1017/S026646231100064X. Int J Technol Assess Health Care. 2012. PMID: 22617734
  • Value of information on preference heterogeneity and individualized care.
    Basu A, Meltzer D. Basu A, et al. Med Decis Making. 2007 Mar-Apr;27(2):112-27. doi: 10.1177/0272989X06297393. Med Decis Making. 2007. PMID: 17409362
  • Cost of disorders of the brain in Europe 2010.
    Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; CDBE2010Study Group. Gustavsson A, et al. Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Eur Neuropsychopharmacol. 2011. PMID: 21924589
  • Preference for place-of-death among terminally ill cancer patients in Denmark.
    Neergaard MA, Jensen AB, Sondergaard J, Sokolowski I, Olesen F, Vedsted P. Neergaard MA, et al. Scand J Caring Sci. 2011 Dec;25(4):627-36. doi: 10.1111/j.1471-6712.2011.00870.x. Epub 2011 Mar 1. Scand J Caring Sci. 2011. PMID: 21362004
See all similar articles

Cited by 5 articles

Publication types

LinkOut - more resources